Irvine, California 92697

  • Schizophrenia

Purpose:

The purpose of this study is to better understand brain function and psychiatric and neurological illness when taking Invega or Risperdal. The objective is to compare the brain effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be evaluated with PET imaging, fMRI, and neurological ratings and assessments.


Criteria:

Inclusion Criteria: - are currently taking Risperdal and have been on the medication for at least three weeks - are diagnosed with schizophrenia - are able to provide written informed consent - can safely have an MRI Exclusion Criteria: - are treatment resistant or intolerant to Risperdal - have participated in another drug study in the past 28 days - are pregnant or trying to become pregnant or are breastfeeding - are colorblind - have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the study - have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant - certain medications are also exclusionary including aripiprazole.


NCT ID:

NCT00937261


Primary Contact:

Principal Investigator
Steven G Potkin, M.D.
UC Irvine

Liv McMillan, B.S.
Phone: 949-824-3770
Email: liv@uci.edu


Backup Contact:

Email: sgpotkin@uci.edu
Steven G Potkin, M.D.
Phone: 714-456-5697


Location Contact:

Irvine, California 92697
United States

Steven G Potkin, M.D.
Phone: 949-824-8040
Email: sgpotkin@uci.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 17, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.